Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: Influence of poor tissue preservation

American Journal of Surgical Pathology

Volumn 36, Issue 10, 2012, Pages 1489-1496

  Schiavon, Beatriz N ^a   Jasani, Bharat ^d   De Brot, Louise ^a   Vassallo, José ^b   Damascena, Aline ^a   Cirullo Neto, Julio ^a   Ivanildo Neves, José ^a   Augusto Soares, Fernando ^a   Gobbi, Helenice ^c   Malagoli Rocha, Rafael ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

breast cancer; HER2; in situ hybridization; SISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ARTIFACT; BREAST TUMOR; CANCER STAGING; COMMUNITY CARE; COMPARATIVE STUDY; EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; REPRODUCIBILITY; TERTIARY HEALTH CARE; TISSUE MICROARRAY; TISSUE PRESERVATION;

ADULT; AGED; ARTIFACTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMMUNITY HEALTH SERVICES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TERTIARY CARE CENTERS; TISSUE ARRAY ANALYSIS; TISSUE PRESERVATION;

EID: 84866617479     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182635987     Document Type: Article

References (21)

1. Bast RC, Ravdin JP, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
2. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathol. 2005;36:250-261.
3. Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP Guideline recommendations: impact on selecting patients for Herceptin therapy. Am J Clin Pathol. 2008;129:907-911.
4. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
5. Brugmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19:203-211.
6. Nassiri M, Ramos S, Zohourian H, et al. Preservation of biomolecules in breast cancer tissue by a formalin-free histology system. BMC Clin Pathol. 2008;8:1.
7. Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55:716-723.
8. Shousha S, Peston D, Amo-Takyi B, et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology. 2009;54:248-253.
9. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med. 2009;133:775-780.
10. Di Palma S, Collins N, Bilous M, et al. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol. 2008;61:757-760.
11. Chibon F, de Mascarel I, Sierankowski G, et al. Prediction of HER2 gene status in Her2 2\+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Modern Pathol. 2009;22:403-409.
12. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539-548.
13. Khoury T, Kulkarni S, Morrison C, et al. HER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2011;19:424-430.
14. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Modern Pathol. 2008;21:1271-1277.
15. Groenen PJ, Blokx WA, Diepenbroek C, et al. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology. 2011;59:1-7.
16. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol. 2010;34:767-776.
17. Garcia-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology. 2010;56:472-480.
18. Rosenberg CL. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J Clin Oncol. 2008;26:4856-4858.
19. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Modern Pathol. 2005;18:1015-1021.
20. Fritzsche FR, Bode PK, Moch H, et al. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Am J Surg Pathol. 2010;34:1180-1185.
21. Bartlett JM, Campbell FM, Ibrahim M, et al. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol. 2009;132:514-520.